Senate investigation: drugmaker harmed sufferers, profited, with asthma inhaler switch
In 2024, medical doctors and fogeys scrambled to search out an inexpensive asthma inhaler after drugmaker GSK pulled the favored Flovent off the market. A senator launched an investigation to search out out what occurred, sharing her findings solely with NCS.